CCM
TEVA icon

Catalio Capital Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Catalio Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,170,372
Closed -$19.6M – 46
2025
Q2 		$19.6M Buy
+1,170,372
New +$18.9M 4.11% 11

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

Catalio Capital Management's TEVA Position: Q3 2025 in Review

Catalio Capital Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q3 2025, closing a stake of 1,170,372 shares — an estimated $19.6M sold.

Catalio Capital Management first reported a position in TEVA in Q2 2025 and held it in 1 quarter. The position peaked at $19.6M in Q2 2025. 551 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.

  • Catalio Capital Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q3 2025 after selling out during the quarter.
  • Catalio Capital Management sold 1,170,372 Teva Pharmaceutical Industries Limited shares in Q3 2025, an estimated $19.6M.
  • Catalio Capital Management first reported a position in Teva Pharmaceutical Industries Limited in Q2 2025 and held it in 1 quarter.
  • Catalio Capital Management's Teva Pharmaceutical Industries Limited position peaked at $19.6M in Q2 2025.
  • 551 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2025.

Based on Catalio Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.